Smith & Nephew plc, founded in 1856 and headquartered in London, is a global medical technology company dedicated to wound management, surgical devices, and orthopedics. The company is known for its innovative products such as advanced wound care solutions, robotic-assisted surgery systems, and orthopedic implants.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| SNLN 2.03% 2030-10-14 USDSmith & Nephew plc | United Kingdom | 2030-10-14 | 2.032 | 4.37 |
| SNLN 4.57% 2029-10-11 EURSmith & Nephew plc | United Kingdom | 2029-10-11 | 4.565 | 2.96 |
| SNLN 5.15% 2027-03-20 USDSmith & Nephew plc | United Kingdom | 2027-03-20 | 5.150 | 3.95 |
| SNLN 5.40% 2034-03-20 USDSmith & Nephew plc | United Kingdom | 2034-03-20 | 5.400 | 4.86 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
In 2020, Smith & Nephew issued €500 million of senior unsecured bonds, marking their first foray into the Eurobond market aimed at refinancing existing debt and enhancing liquidity. The 10-year bond had a yield of 1.625%, appealing to investors amid a backdrop of low-interest rates. Historically, the company has maintained an active presence in capital markets, including notable bond issuances in 2017 for $1 billion to finance acquisitions. Current yields remain competitive within the medical technology sector, reflecting strong investor confidence in Smith & Nephew’s financial stability and growth prospects.